TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2026 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2026 Earnings Call Transcript May 12, 2026TriSalus Life Sciences, Inc. misses on earnings expectations.
Trisalus Life Sciences Inc. (TLSI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,070,827 | $8,283,308 | 0.3% | |
| 2. | Royce & Associates Chuck Royce | 200,060 | $800,240 | 0.01% | |
| 3. | MSDC Management Marc Lisker, Glenn Fuhrman And John Phelan | 39,999 | $159,996 | 0.19% | |
| 4. | Renaissance Technologies Jim Simons | 30,900 | $123,600 | 0% | |
| 5. | Ghisallo Capital Management Michael Germino | 25,000 | $100,000 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.53 | 60,000 | $151,800.00 | 147,555 | 2026-05-15 | Filing | |
| $2.50 | 200,000 | $500,000.00 | 399,698 | 2026-05-15 | Filing | |
| $2.50 | 410,000 | $1,025,000.00 | 1,240,722 | 2026-05-15 | Filing | |
| $2.59 | 39,682 | $102,776.38 | 1,065,215 | 2026-05-15 | Filing | |
| $2.43 | 7,100 | $17,253.00 | 275,757 | 2026-05-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.67 | 543 | $1,449.81 | 125,101 | 2026-05-15 | Filing | |
| $4.12 | 273 | $1,124.76 | 97,364 | 2026-03-16 | Filing | |
| $4.09 | 1,772 | $7,247.48 | 97,637 | 2026-03-12 | Filing | |
| $4.13 | 1,162 | $4,799.06 | 99,409 | 2026-03-11 | Filing | |
| $4.12 | 579 | $2,385.48 | 163,415 | 2026-03-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,066,827 | $20,267,308 | 1.82% | |
| 2. | 2,079,105 | $8,316,420 | 0.92% | |
| 3. | 1,499,547 | $5,998,188 | 0% | |
| 4. | 1,437,960 | $5,751,840 | 0.04% | |
| 5. | 1,347,036 | $5,388,144 | 0% |
News See All
8 Best Fast Growing Penny Stocks to Buy Right Now
On May 4, Gregory Daco, EY-Parthenon Chief Economist, joined CNBC's 'Squawk Box' to discuss the current state of the US economy and the Fed's likely trajectory.
Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating
On March 6, 2026, Canaccord analyst William Plovanic lowered the price target on TriSalus Life Sciences, Inc. (NASDAQ:TLSI) to $7 from $12 previously and maintained a Buy rating.
11 Fastest Growing Penny Stocks to Buy Right Now
Interest in smaller companies has been quietly building on Wall Street.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2025 Earnings Call Transcript
Operator: Good day, and welcome to the TriSalus Life Sciences Fourth Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q3 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q3 2025 Earnings Call Transcript November 13, 2025TriSalus Life Sciences, Inc. misses on earnings expectations.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2025 Earnings Call Transcript August 12, 2025TriSalus Life Sciences, Inc. misses on earnings expectations.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2025 Earnings Call Transcript May 15, 2025TriSalus Life Sciences, Inc. misses on earnings expectations.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2024 Earnings Call Transcript March 27, 2025TriSalus Life Sciences, Inc. reports earnings inline with expectations.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q3 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q3 2024 Earnings Call Transcript November 14, 2024TriSalus Life Sciences, Inc. misses on earnings expectations.